TrialAn Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
Trial details
- Registry ID
- NCT05645432
- Phase
- Phase 2
Drug research
Brexanolone
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Allopregnanolone; SAGE-547; ZULRESSO®
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| An Open-Label Study Evaluating Brexanolone in Adults With TinnitusNCT05645432 | SUPN | Phase 2 | Completed | 2023-11-21Actual |
| A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)NCT03665038 | SUPN | Phase 3 | Completed | 2021-01-08Actual |
A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
Trial details
- Registry ID
- NCT03665038
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |